Relmada Secures $160M Financing, Reports Strong NDV-01 Phase 2 Data, Extends Cash Runway to 2029

summarizeSummary

Relmada Therapeutics announced positive 12-month Phase 2 data for NDV-01 in bladder cancer, secured an oversubscribed $160 million PIPE financing, and extended its cash runway through 2029.

check_boxKey Events

• Successful $160M PIPE Financing

  Relmada completed an oversubscribed private placement, raising $160 million in gross proceeds in March 2026, demonstrating strong investor confidence.

• Extended Cash Runway

  The company's cash balance, including the PIPE proceeds, is expected to fund operations through 2029, covering the completion of the Phase 3 NDV-01 RESCUE program.

• Positive NDV-01 Phase 2 Data

  12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer showed a 95% complete response rate at any time and a durable 76% complete response rate at 12 months, with a favorable safety profile.

• Phase 3 Program Advancement

  Relmada is on track to initiate the Phase 3 RESCUE registrational program for NDV-01 in mid-2026, targeting two independent approval pathways.

auto_awesomeAnalysis

This 8-K highlights a pivotal moment for Relmada Therapeutics, combining strong clinical progress with a significant financial boost. The positive 12-month Phase 2 data for NDV-01, demonstrating a 76% durable complete response rate in high-risk non-muscle invasive bladder cancer, de-risks the lead program and provides a strong foundation for the upcoming Phase 3 RESCUE program. The oversubscribed $160 million PIPE financing underscores strong investor confidence and significantly strengthens the balance sheet. Critically, this financing, combined with existing cash, is projected to fund operations through 2029, removing near-term funding concerns and providing a clear path to complete the registrational Phase 3 program. Investors should view this as a major positive catalyst, validating the company's pipeline and financial stability.